Burning Rock Biotech Ltd. ADR (BNR): Price and Financial Metrics
GET POWR RATINGS... FREE!
BNR Stock Price Chart Interactive Chart >
BNR Price/Volume Stats
| Current price | $2.41 | 52-week high | $14.00 |
| Prev. close | $2.54 | 52-week low | $1.70 |
| Day low | $2.35 | Volume | 184,400 |
| Day high | $2.65 | Avg. volume | 464,265 |
| 50-day MA | $2.25 | Dividend yield | N/A |
| 200-day MA | $4.14 | Market Cap | 253.50M |
Burning Rock Biotech Ltd. ADR (BNR) Company Bio
Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The company operates through following segment: central laboratory business, in-hospital business and pharma research and development services. Its products and clinical applications including companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. Burning Rock Biotech was founded by Yu Sheng Han in 2014 and is headquartered in Guangzhou, China.
Latest BNR News From Around the Web
Below are the latest news stories about BURNING ROCK BIOTECH LTD that investors may wish to consider to help them evaluate BNR as an investment opportunity.
Burning Rock Biotech Limited Sponsored ADR (BNR) Upgraded to Buy: What Does It Mean for the Stock?Burning Rock Biotech Limited Sponsored ADR (BNR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic among traders this morning as we cover all of the biggest news moving shares on Wednesday! |
Burning Rock Reports Third Quarter 2022 Financial ResultsGUANGZHOU, China, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2022. Recent Business Updates Corporate Listed on the Main Market of the London Stock Exchange (the "LSE") by way of a direct listing on November 1, 2022, while Bur |
Burning Rock Biotech Second Quarter 2022 Earnings: Misses ExpectationsBurning Rock Biotech ( NASDAQ:BNR ) Second Quarter 2022 Results Key Financial Results Revenue: CN¥130.8m (up 2.8% from... |
Admission to Trading on the London Stock ExchangeNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. BURNING ROCK BIOTECH LIMITED – Admission to Trading on the London Stock Exchange 1 November 2022 Neither this announcement, nor anything contained herein, nor anything contained in the prospectus (the “Prospectus”) referred to herein shall form the basis of, or be relied upon in con |
BNR Price Returns
| 1-mo | 23.59% |
| 3-mo | -24.45% |
| 6-mo | 19.90% |
| 1-year | -79.88% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -74.71% |
| 2021 | -58.74% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...